Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Review on Emerging Therapeutic Strategies for Managing Cardiovascular Disease

Author(s): Minal Narkhede*, Avinash Pardeshi, Rahul Bhagat and Gajanan Dharme

Volume 20, Issue 4, 2024

Published on: 16 April, 2024

Article ID: e160424228949 Pages: 15

DOI: 10.2174/011573403X299265240405080030

Price: $65

Abstract

Cardiovascular disease (CVD) remains a foremost global health concern, necessitating ongoing exploration of innovative therapeutic strategies. This review surveys the latest developments in cardiovascular therapeutics, offering a comprehensive overview of emerging approaches poised to transform disease management. The examination begins by elucidating the current epidemiological landscape of CVD and the economic challenges it poses to healthcare systems. It proceeds to scrutinize the limitations of traditional therapies, emphasizing the need for progressive interventions.

The core focus is on novel pharmacological interventions, including advancements in drug development, targeted therapies, and repurposing existing medications. The burgeoning field of gene therapy and its potential in addressing genetic predispositions to cardiovascular disorders are explored, alongside the integration of artificial intelligence and machine learning in risk assessment and treatment optimization.

Non-pharmacological interventions take center stage, with an exploration of digital health technologies, wearable devices, and telemedicine as transformative tools in CVD management. Regenerative medicine and stem cell therapies, offering promises of tissue repair and functional recovery, are investigated for their potential impact on cardiac health.

This review also delves into the interplay of lifestyle modifications, diet, exercise, and behavioral changes, emphasizing their pivotal role in cardiovascular health and disease prevention. As precision medicine gains prominence, this synthesis of emerging therapeutic modalities aims to guide clinicians and researchers in navigating the dynamic landscape of cardiovascular disease management, fostering a collective effort to alleviate the global burden of CVD and promote a healthier future.

Graphical Abstract

[1]
Rosvall M, Engström G, Berglund G, Hedblad B. C-reactive protein, established risk factors and social inequalities in cardiovascular disease – The significance of absolute versus relative measures of disease. BMC Public Health 2008; 8(1): 189.
[http://dx.doi.org/10.1186/1471-2458-8-189]
[2]
Sharabi Y, Ben-Cnaan R, Hanin A, Martonovitch G, Grossman E. The significance of hypertensive response to exercise as a predictor of hypertension and cardiovascular disease. J Hum Hypertens 2001; 15(5): 353-6.
[http://dx.doi.org/10.1038/sj.jhh.1001157] [PMID: 11378838]
[3]
Balbirsingh V, Mohammed AS, Turner AM, Newnham M. Cardiovascular disease in chronic obstructive pulmonary disease: A narrative review. Thorax 2022; 77(9): 939-45.
[http://dx.doi.org/10.1136/thoraxjnl-2021-218333] [PMID: 35772939]
[4]
Congdon JM. Cardiovascular disease.In: Canine and Feline Anesthesia and Co‐Existing Disease. Wiley 2022; pp. 1-85.
[http://dx.doi.org/10.1002/9781119604075.ch1]
[5]
Behera S, Pramanik K, Nayak M. Recent advancement in the treatment of cardiovascular diseases: Conventional therapy to nanotechnology. Curr Pharm Des 2015; 21(30): 4479-97.
[http://dx.doi.org/10.2174/1381612821666150817104635] [PMID: 26278923]
[6]
Silva IGR, Pantoja BTS, Almeida GHDR, Carreira ACO, Miglino MA. Bacterial cellulose and ECM hydrogels: An innovative approach for cardiovascular regenerative medicine. Int J Mol Sci 2022; 23(7): 3955.
[http://dx.doi.org/10.3390/ijms23073955] [PMID: 35409136]
[7]
Swerdlow DI, Rider DA, Yavari A, Wikström Lindholm M, Campion GV, Nissen SE. Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: The emerging potential of RNA interference therapeutics. Cardiovasc Res 2022; 118(5): 1218-31.
[http://dx.doi.org/10.1093/cvr/cvab100] [PMID: 33769464]
[8]
Ogut E, Armagan K, Tufekci D, Mathieu D. The Guillain-Mollaret triangle: A key player in motor coordination and control with implications for neurological disorders. Neurosurg Rev 2023; 46(1): 181-90.
[http://dx.doi.org/10.1007/s10143-023-02086-1] [PMID: 37468768]
[9]
Saiz LC, Gorricho J, Garjón J, Celaya MC, Erviti J, Leache L. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev 2022; 11(11): CD010315.
[PMID: 36398903]
[10]
Trimarco V, Izzo R, Morisco C, et al. High HDL (high-density lipoprotein) cholesterol increases cardiovascular risk in hypertensive patients. Hypertension 2022; 79(10): 2355-63.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.122.19912] [PMID: 35968698]
[11]
Wu AD, Lindson N, Boyce HJ, et al. Smoking cessation for secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2022; 8(8): CD014936.
[PMID: 35938889]
[12]
Lopez-Jimenez F, Almahmeed W, Bays H, et al. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. Eur J Prev Cardiol 2022; 29(17): 2218-37.
[http://dx.doi.org/10.1093/eurjpc/zwac187] [PMID: 36007112]
[13]
Schmidt AM. Diabetes mellitus and cardiovascular disease. Arterioscler Thromb Vasc Biol 2019; 39(4): 558-68.
[http://dx.doi.org/10.1161/ATVBAHA.119.310961] [PMID: 30786741]
[14]
Al-Saber A, May AN. Effect of mindful meditation, physical activity, and diet to reduce the risk to develop or reduce severity of cardiovascular diseases in Saudi Arabia: A systematic review. World J Cardiovasc Dis 2023; 13(1): 46-72.
[http://dx.doi.org/10.4236/wjcd.2023.131005]
[15]
Kazemi A, Sasani N, Mokhtari Z, et al. Comparing the risk of cardiovascular diseases and all-cause mortality in four lifestyles with a combination of high/low physical activity and healthy/unhealthy diet: A prospective cohort study. Int J Behav Nutr Phys Act 2022; 19(1): 138.
[http://dx.doi.org/10.1186/s12966-022-01374-1] [PMID: 36384713]
[16]
Kundu J, Kundu S. Cardiovascular disease (CVD) and its associated risk factors among older adults in India: Evidence from LASI Wave 1. Clin Epidemiol Glob Health 2021; 2022(13): 16-20.
[17]
Popovic D, Bjelobrk M, Tesic M, et al. Defining the importance of stress reduction in managing cardiovascular disease - The role of exercise. Prog Cardiovasc Dis 2022; 70: 84-93.
[http://dx.doi.org/10.1016/j.pcad.2022.01.008] [PMID: 35131232]
[18]
Biddinger KJ, Emdin CA, Haas ME, et al. Association of habitual alcohol intake with risk of cardiovascular disease. JAMA Netw Open 2022; 5(3): e223849.
[http://dx.doi.org/10.1001/jamanetworkopen.2022.3849] [PMID: 35333364]
[19]
Karami N, Kazeminia M, Karami A, Salimi Y, Ziapour A, Janjani P. Global prevalence of depression, anxiety, and stress in cardiac patients: A systematic review and meta-analysis. J Affect Disord 2023; 324: 175-89.
[http://dx.doi.org/10.1016/j.jad.2022.12.055] [PMID: 36584710]
[20]
Şahin B, İlgün G. Risk factors of deaths related to cardiovascular diseases in World Health Organization (WHO) member countries. Health Soc Care Community 2022; 30(1): 73-80.
[http://dx.doi.org/10.1111/hsc.13156] [PMID: 32909378]
[21]
Marquina C, Talic S, Torres VS, et al. Future burden of cardiovascular disease in Australia: Impact on health and economic outcomes between 2020 and 2029. Eur J Prev Cardiol 2022; 29(8): 1212-9.
[http://dx.doi.org/10.1093/eurjpc/zwab001] [PMID: 33686414]
[22]
Clayton JA, Gaugh MD. Sex as a biological variable in cardiovascular diseases. J Am Coll Cardiol 2022; 79(14): 1388-97.
[http://dx.doi.org/10.1016/j.jacc.2021.10.050] [PMID: 35393021]
[23]
Magnussen C, Ojeda FM, Leong DP, et al. Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med 2023; 389(14): 1273-85.
[http://dx.doi.org/10.1056/NEJMoa2206916] [PMID: 37632466]
[24]
Chang WH, Mueller SH, Chung SC, Foster GR, Lai AG. Increased burden of cardiovascular disease in people with liver disease: Unequal geographical variations, risk factors and excess years of life lost. J Transl Med 2022; 20(1): 2.
[http://dx.doi.org/10.1186/s12967-021-03210-9] [PMID: 34980174]
[25]
Kempen TGH, Hedman AN, Hadziosmanovic N, et al. Risk factors for and preventability of drug‐related hospital revisits in older patients: A post‐hoc analysis of a randomized clinical trial. Br J Clin Pharmacol 2023; 89(5): 1575-87.
[http://dx.doi.org/10.1111/bcp.15621] [PMID: 36454520]
[26]
Strauss MH, Hall AS, Narkiewicz K. The combination of beta-blockers and ACE inhibitors across the spectrum of cardiovascular diseases. Cardiovasc Drugs Ther 2023; 37(4): 757-70.
[http://dx.doi.org/10.1007/s10557-021-07248-1] [PMID: 34533690]
[27]
Susilo H, Pikir BS, Thaha M, Alsagaff MY. The effect of angiotensin converting enzyme (ACE) I/D polymorphism on atherosclerotic cardiovascular disease and cardiovascular mortality risk in non-hemodialyzed chronic kidney disease: The mediating role of plasma ACE level. Genes 2022; 13(7): 1121.
[28]
Passacquale G, Ferro A. Antiplatelet therapy in cardiovascular disease: Current status and future directions. Br J Clin Pharmacol 2021; 88(6): 2686-99.
[29]
D’Amario D, Galli M, Restivo A, Canonico F, Vergallo R, Migliaro S. Ticagrelor enhances the cardioprotective effects of ischemic preconditioning in stable patients undergoing percutaneous coronary intervention: The TAPER-S randomized study. Eur Hear J -Cardiovasc Pharmacother 2023; pvad092.
[http://dx.doi.org/10.1093/ehjcvp/pvad092]
[30]
Tamargo J, Kjeldsen KP, Delpón E, Semb AG, Cerbai E, Dobrev D. Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the european society of cardiology working group on cardiovascular pharmacotherapy. Eur Heart J Cardiovasc Pharmacother 2022; 8(4): 406-19.
[31]
Groenland EH, Vendeville JP, Bots ML. The relation between urinary sodium and potassium excretion and risk of cardiovascular events and mortality in patients with cardiovascular disease. PLoS One 2022; 17(3): e0265429.
[32]
Szczepańska E, Białek-Dratwa A, Janota B, Kowalski O. Dietary therapy in prevention of cardiovascular disease (CVD)—tradition or modernity? a review of the latest approaches to nutrition in CVD. Nutrients 2022; 14(13): 2649.
[http://dx.doi.org/10.3390/nu14132649] [PMID: 35807830]
[33]
Tucker WJ, Fegers-Wustrow I, Halle M, Haykowsky MJ, Chung EH, Kovacic JC. Exercise for primary and secondary prevention of cardiovascular disease. J Am Coll Cardiol 2022; 80(11): 1091-106.
[http://dx.doi.org/10.1016/j.jacc.2022.07.004] [PMID: 36075680]
[34]
Robijn AL, Woodward M, Pearson SA, et al. Uptake of prescription smoking cessation pharmacotherapies after hospitalization for major cardiovascular disease. Eur J Prev Cardiol 2022; 29(17): 2173-82.
[http://dx.doi.org/10.1093/eurjpc/zwac172] [PMID: 35950363]
[35]
McEvoy LK, Bergstrom J, Tu X, et al. Moderate alcohol use is associated with reduced cardiovascular risk in middle-aged men independent of health, behavior, psychosocial, and earlier life factors. Nutrients 2022; 14(11): 2183.
[http://dx.doi.org/10.3390/nu14112183] [PMID: 35683983]
[36]
Nelson AJ, Navar AM, Mulder H, et al. Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the bypass angioplasty revascularization investigation 2 diabetes [BARI 2D] trial). Am J Cardiol 2020; 132: 36-43.
[http://dx.doi.org/10.1016/j.amjcard.2020.07.005] [PMID: 32773223]
[37]
Chacko L, P Howard J, Rajkumar C, et al. Effects of percutaneous coronary intervention on death and myocardial infarction stratified by stable and unstable coronary artery disease: A meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2020; 13(2): e006363.
[http://dx.doi.org/10.1161/CIRCOUTCOMES.119.006363] [PMID: 32063040]
[38]
Park DW, Ahn JM, Park H, et al. Ten-year outcomes after drug-eluting stents versus coronary artery bypass grafting for left main coronary disease. Circulation 2020; 141(18): 1437-46.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.046039] [PMID: 32223567]
[39]
Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American heart association. Arterioscler Thromb Vasc Biol 2022; 42(1): e48-60.
[http://dx.doi.org/10.1161/ATV.0000000000000147] [PMID: 34647487]
[40]
McDonough CW. Pharmacogenomics in cardiovascular diseases. Curr Protoc 2021; 1(7): e189.
[http://dx.doi.org/10.1002/cpz1.189] [PMID: 34232575]
[41]
Wang Y. Identification of cardiovascular diseases based on machine learning. ISAIMS ’22: Proceedings of the 3rd International Symposium on Artificial Intelligence for Medicine Sciences. October 13 - 15, 2022; Amsterdam Netherlands. 2022; 531-6.
[http://dx.doi.org/10.1145/3570773.3570855]
[42]
Zheng F, Ding S, Lai L, et al. Relationship between medication literacy and medication adherence in inpatients with coronary heart disease in Changsha, China. Front Pharmacol 2020; 10(January): 1537.
[http://dx.doi.org/10.3389/fphar.2019.01537] [PMID: 32009954]
[43]
Carson JAS, Lichtenstein AH, Anderson CAM, et al. Dietary cholesterol and cardiovascular risk: A science advisory from the american heart association. Circulation 2020; 141(3): e39-53.
[http://dx.doi.org/10.1161/CIR.0000000000000743] [PMID: 31838890]
[44]
Rippe JM. Lifestyle strategies for risk factor reduction, prevention, and treatment of cardiovascular disease. Am J Lifestyle Med 2019; 13(2): 204-12.
[http://dx.doi.org/10.1177/1559827618812395] [PMID: 30800027]
[45]
Roberts R, Chang CC, Hadley T. Genetic risk stratification. JACC Basic Transl Sci 2021; 6(3): 287-304.
[http://dx.doi.org/10.1016/j.jacbts.2020.09.004] [PMID: 33778213]
[46]
Ullah M, Hamayun S, Wahab A, et al. Smart technologies used as smart tools in the management of cardiovascular disease and their future perspective. Curr Probl Cardiol 2023; 48(11): 101922.
[http://dx.doi.org/10.1016/j.cpcardiol.2023.101922] [PMID: 37437703]
[47]
Coorey G, Figtree GA, Fletcher DF, Snelson VJ, Vernon ST, Winlaw D. The health digital twin to tackle cardiovascular disease—A review of an emerging interdisciplinary field. NPJ Digit Med 2022; 5(1)
[48]
Hamad R, Glymour MM, Calmasini C, Nguyen TT, Walter S, Rehkopf DH. Explaining the variance in cardiovascular disease risk factors. Epidemiology 2022; 33(1): 25-33.
[http://dx.doi.org/10.1097/EDE.0000000000001425] [PMID: 34799480]
[49]
Samidurai A, Das A. Cardiovascular complications associated with COVID-19 and potential therapeutic strategies. Int J Mol Sci 2020; 21(18): 6790.
[http://dx.doi.org/10.3390/ijms21186790] [PMID: 32947927]
[50]
Alfaddagh A, Martin SS, Leucker TM, et al. Inflammation and cardiovascular disease: From mechanisms to therapeutics. Am J Prev Med 2020; 4(10): 100130.
[http://dx.doi.org/10.1016/j.ajpc.2020.100130] [PMID: 34327481]
[51]
Persson R, Hagberg KW, Qian Y, Scaramozza VC, Jick S. The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids. Rheumatology 2021; 60(4): 1926-31.
[http://dx.doi.org/10.1093/rheumatology/keaa683] [PMID: 33159794]
[52]
Sinh P, Cross R. Cardiovascular risk assessment and impact of medications on cardiovascular disease in inflammatory bowel disease. Inflamm Bowel Dis 2021; 27(7): 1107-15.
[http://dx.doi.org/10.1093/ibd/izaa258] [PMID: 32978937]
[53]
Drobni ZD, Alvi RM, Taron J, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 2020; 142(24): 2299-311.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.049981] [PMID: 33003973]
[54]
Waheed N, Fradley MG, DeRemer DL, et al. Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: A retrospective analysis of patients at an academic tertiary care center. Cardiooncology 2021; 7(1): 10.
[http://dx.doi.org/10.1186/s40959-021-00097-9] [PMID: 33736707]
[55]
Montisci A, Vietri MT, Palmieri V, Sala S, Donatelli F, Napoli C. Cardiac toxicity associated with cancer immunotherapy and biological drugs. Cancers 2021; 13(19): 4797.
[http://dx.doi.org/10.3390/cancers13194797] [PMID: 34638281]
[56]
Pala R, Anju VT, Dyavaiah M, Busi S, Nauli SM. Nanoparticle-mediated drug delivery for the treatment of cardiovascular diseases. Int J Nanomedicine 2020; 15: 3741-69.
[http://dx.doi.org/10.2147/IJN.S250872] [PMID: 32547026]
[57]
Deng Y, Zhang X, Shen H, et al. Application of the nano-drug delivery system in treatment of cardiovascular diseases. Front Bioeng Biotechnol 2020; 7(January): 489.
[http://dx.doi.org/10.3389/fbioe.2019.00489] [PMID: 32083068]
[58]
Vazquez-Prada KX, Lam J, Kamato D, Xu ZP, Little PJ, Ta HT. Targeted molecular imaging of cardiovascular diseases by iron oxide nanoparticles. Arterioscler Thromb Vasc Biol 2021; 41(2): 601-13.
[http://dx.doi.org/10.1161/ATVBAHA.120.315404] [PMID: 33356385]
[59]
Abdar M, Książek W, Acharya UR, Tan RS, Makarenkov V, Pławiak P. A new machine learning technique for an accurate diagnosis of coronary artery disease. Comput Methods Programs Biomed 2019; 179: 104992.
[http://dx.doi.org/10.1016/j.cmpb.2019.104992] [PMID: 31443858]
[60]
Wang DK, Rahimi M, Filgueira CS. Nanotechnology applications for cardiovascular disease treatment: Current and future perspectives. Nanomedicine 2021; 34: 102387.
[http://dx.doi.org/10.1016/j.nano.2021.102387] [PMID: 33753283]
[61]
Wernly B, Mirna M, Rezar R, et al. Regenerative cardiovascular therapies: Stem cells and beyond. Int J Mol Sci 2019; 20(6): 1420.
[http://dx.doi.org/10.3390/ijms20061420] [PMID: 30901815]
[62]
Guo Y, Yu Y, Hu S, Chen Y, Shen Z. The therapeutic potential of mesenchymal stem cells for cardiovascular diseases. Cell Death Dis 2020; 11(5): 349.
[http://dx.doi.org/10.1038/s41419-020-2542-9] [PMID: 32393744]
[63]
Madonna R, Van Laake LW, Botker HE, et al. ESC working group on cellular biology of the heart: Position paper for cardiovascular research: Tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure. Cardiovasc Res 2019; 115(3): 488-500.
[http://dx.doi.org/10.1093/cvr/cvz010] [PMID: 30657875]
[64]
Liu N, Ye X, Yao B, et al. Advances in 3D bioprinting technology for cardiac tissue engineering and regeneration. Bioact Mater 2021; 6(5): 1388-401.
[http://dx.doi.org/10.1016/j.bioactmat.2020.10.021] [PMID: 33210031]
[65]
Sun Y, Lu Y, Yin L, Liu Z. The roles of nanoparticles in stem cell-based therapy for cardiovascular disease. Front Bioeng Biotechnol 2020; 8(August): 947.
[http://dx.doi.org/10.3389/fbioe.2020.00947] [PMID: 32923434]
[66]
Hilty DM, Armstrong CM, Edwards-Stewart A, Gentry MT, Luxton DD, Krupinski EA. Sensor, wearable, and remote patient monitoring competencies for clinical care and training: Scoping review. J Technol Behav Sci 2021; 6(2): 252-77.
[http://dx.doi.org/10.1007/s41347-020-00190-3] [PMID: 33501372]
[67]
Modena BD, Bellahsen O, Nikzad N, et al. Advanced and accurate mobile health tracking devices record new cardiac vital signs. Hypertension 2018; 72(2): 503-10.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.118.11177] [PMID: 29967036]
[68]
Cohn JN, Hoke L, Whitwam W, et al. Screening for early detection of cardiovascular disease in asymptomatic individuals. Am Heart J 2003; 146(4): 679-85.
[http://dx.doi.org/10.1016/S0002-8703(03)00499-X] [PMID: 14564323]
[69]
Köhler KA, Tingström P, Jaarsma T, Nilsson S. Patient empowerment and general self-efficacy in patients with coronary heart disease: A cross-sectional study. BMC Fam Pract 2018; 19(1): 76.
[http://dx.doi.org/10.1186/s12875-018-0749-y] [PMID: 29843619]
[70]
Bauersachs R, Zeymer U, Brière JB, Marre C, Bowrin K, Huelsebeck M. Burden of coronary artery disease and peripheral artery disease: A literature review. Cardiovasc Ther 2019; 2019: 8295054.
[http://dx.doi.org/10.1155/2019/8295054]
[71]
Anand SS, Abonyi S, Arbour L, et al. Explaining the variability in cardiovascular risk factors among First Nations communities in Canada: A population-based study. Lancet Planet Health 2019; 3(12): e511-20.
[http://dx.doi.org/10.1016/S2542-5196(19)30237-2] [PMID: 31868600]
[72]
Peirlinck M, Costabal FS, Yao J, et al. Precision medicine in human heart modeling. Biomech Model Mechanobiol 2021; 20(3): 803-31.
[http://dx.doi.org/10.1007/s10237-021-01421-z] [PMID: 33580313]
[73]
Dinh A, Miertschin S, Young A, Mohanty SD. A data-driven approach to predicting diabetes and cardiovascular disease with machine learning. BMC Med Inform Decis Mak 2019; 19(1): 211.
[http://dx.doi.org/10.1186/s12911-019-0918-5] [PMID: 31694707]
[74]
Psotka MA, Fonarow GC, Allen LA, et al. The hospital readmissions reduction program. JACC Heart Fail 2020; 8(1): 1-11.
[http://dx.doi.org/10.1016/j.jchf.2019.07.012] [PMID: 31606360]
[75]
Han X, Chen W, Gao Z, et al. Effectiveness of telemedicine for cardiovascular disease management: Systematic review and meta-analysis. Ann Palliat Med 2021; 10(12): 12831-44.
[http://dx.doi.org/10.21037/apm-21-3626] [PMID: 35016435]
[76]
Fahle S, Prinz C, Kuhlenkötter B. Systematic review on machine learning (ML) methods for manufacturing processes – Identifying artificial intelligence (AI) methods for field application. Procedia CIRP 2020; 93: 413-8.
[http://dx.doi.org/10.1016/j.procir.2020.04.109]
[77]
Kilic A. Artificial intelligence and machine learning in cardiovascular health care. Ann Thorac Surg 2020; 109(5): 1323-9.
[http://dx.doi.org/10.1016/j.athoracsur.2019.09.042] [PMID: 31706869]
[78]
Georga EI, Tachos NS, Sakellarios AI, Kigka VI, Exarchos TP, Pelosi G. Artificial intelligence and data mining methods for cardiovascular risk prediction.In: Cardiovascular Computing—Methodologies and Clinical Applications Golemati S, Nikita K. Singapore: Springer 2019.
[http://dx.doi.org/10.1007/978-981-10-5092-3_14]
[79]
Cresswell K, Callaghan M, Khan S, Sheikh Z, Mozaffar H, Sheikh A. Investigating the use of data-driven artificial intelligence in computerised decision support systems for health and social care: A systematic review. Health Informatics J 2020; 26(3): 2138-47.
[http://dx.doi.org/10.1177/1460458219900452] [PMID: 31964204]
[80]
Kodera S, Akazawa H, Morita H, Komuro I. Prospects for cardiovascular medicine using artificial intelligence. J Cardiol 2022; 79(3): 319-25.
[http://dx.doi.org/10.1016/j.jjcc.2021.10.016] [PMID: 34772574]
[81]
Saffi MAL, Polanczyk CA, Silva RER. Lifestyle interventions reduce cardiovascular risk in patients with coronary artery disease: A randomized clinical trial. Eur J Cardiovasc Nurs 2014; 13(5): 436-43.
[http://dx.doi.org/10.1177/1474515113505396] [PMID: 24021286]
[82]
Mozaffarian D, Afshin A, Benowitz NL, et al. Population approaches to improve diet, physical activity, and smoking habits: A scientific statement from the American Heart Association. Circulation 2012; 126(12): 1514-63.
[http://dx.doi.org/10.1161/CIR.0b013e318260a20b] [PMID: 22907934]
[83]
Fadhil A, Gabrielli S. Addressing challenges in promoting healthy lifestyles. Proceedings of the 11th EAI International Conference on Pervasive Computing Technologies for Healthcare. New York, NY, USA. 2017; pp. 261-5.
[http://dx.doi.org/10.1145/3154862.3154914]
[84]
Tørris C, Mobekk H. Improving cardiovascular health through nudging healthier food choices: A systematic review. Nutrients 2019; 11(10): 2520.
[http://dx.doi.org/10.3390/nu11102520] [PMID: 31635377]
[85]
Richards MR, Sindelar JL. Rewarding healthy food choices in SNAP: Behavioral economic applications. Milbank Q 2013; 91(2): 395-412.
[http://dx.doi.org/10.1111/milq.12017] [PMID: 23758515]
[86]
Chatterjee A, Prinz A, Gerdes M, Martinez S. Digital interventions on healthy lifestyle management: Systematic review. J Med Internet Res 2021; 23(11): e26931.
[http://dx.doi.org/10.2196/26931] [PMID: 34787575]
[87]
Gorski MT, Roberto CA. Public health policies to encourage healthy eating habits: recent perspectives. J Healthc Leadersh 2015; 7(Sep): 81-90.
[PMID: 29355201]
[88]
Davis AJ, Parker HM, Gallagher R. Gamified applications for secondary prevention in patients with high cardiovascular disease risk: A systematic review of effectiveness and acceptability. J Clin Nurs 2021; 30(19-20): 3001-10.
[http://dx.doi.org/10.1111/jocn.15808] [PMID: 33872436]
[89]
Alahäivälä T, Kukkonen OH. Understanding persuasion contexts in health gamification: A systematic analysis of gamified health behavior change support systems literature. Int J Med Inform 2016; 96: 62-70.
[http://dx.doi.org/10.1016/j.ijmedinf.2016.02.006] [PMID: 26944611]
[90]
McCarty NS, Graham AE, Studená L, Amaro LR. Multiplexed CRISPR technologies for gene editing and transcriptional regulation. Nat Commun 2020; 11(1): 1281.
[http://dx.doi.org/10.1038/s41467-020-15053-x] [PMID: 32152313]
[91]
Cring MR, Sheffield VC. Gene therapy and gene correction: Targets, progress, and challenges for treating human diseases. Gene Ther 2022; 29(1-2): 3-12.
[http://dx.doi.org/10.1038/s41434-020-00197-8] [PMID: 33037407]
[92]
Jiang C, Meng L, Yang B, Luo X. Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment. Clin Genet 2020; 97(1): 73-88.
[http://dx.doi.org/10.1111/cge.13589] [PMID: 31231788]
[93]
Shi TQ, Gao J, Wang WJ, et al. CRISPR/Cas9-based genome editing in the filamentous fungus Fusarium fujikuroi and its application in strain engineering for gibberellic acid production. ACS Synth Biol 2019; 8(2): 445-54.
[http://dx.doi.org/10.1021/acssynbio.8b00478] [PMID: 30616338]
[94]
Zhang H, Qin C, An C, et al. Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer 2021; 20(1): 126.
[http://dx.doi.org/10.1186/s12943-021-01431-6] [PMID: 34598686]
[95]
Shinwari ZK, Tanveer F, Khalil AT. Ethical issues regarding CRISPR mediated genome editing. Curr Issues Mol Biol 2018; 26: 103-10.
[http://dx.doi.org/10.21775/cimb.026.103] [PMID: 28879860]
[96]
Niemiec E, Howard HC. Germline genome editing research: What are gamete donors (Not) informed about in consent forms? CRISPR J 2020; 3(1): 52-63.
[http://dx.doi.org/10.1089/crispr.2019.0043] [PMID: 32091253]
[97]
Mulvihill JJ, Capps B, Joly Y, Lysaght T, Zwart HAE, Chadwick R. Ethical issues of CRISPR technology and gene editing through the lens of solidarity. Br Med Bull 2017; 122(1): 17-29.
[http://dx.doi.org/10.1093/bmb/ldx002] [PMID: 28334154]
[98]
Cipriani M, Pichiorri F, Colamarino E, et al. The Promotoer, a brain-computer interface-assisted intervention to promote upper limb functional motor recovery after stroke: A statistical analysis plan for a randomized controlled trial. Trials 2023; 24(1): 736.
[http://dx.doi.org/10.1186/s13063-023-07773-4] [PMID: 37974284]
[99]
Patterson K, Davey R, Keegan R, et al. Testing the effect of a smartphone app on hospital admissions and sedentary behavior in cardiac rehabilitation participants: ToDo-CR randomized controlled trial. JMIR Mhealth Uhealth 2023; 11: e48229.
[http://dx.doi.org/10.2196/48229] [PMID: 37788043]
[100]
Wang KL, Meah MN, Bularga A, et al. Early computed tomography coronary angiography and preventative treatment in patients with suspected acute coronary syndrome: A secondary analysis of the RAPID-CTCA trial. Am Heart J 2023; 266: 138-48.
[http://dx.doi.org/10.1016/j.ahj.2023.09.003] [PMID: 37709109]
[101]
Mistry EA, Hart KW, Davis LT, et al. Blood pressure management after endovascular therapy for acute ischemic stroke. JAMA 2023; 330(9): 821-31.
[http://dx.doi.org/10.1001/jama.2023.14330] [PMID: 37668620]
[102]
Zheng B, Li Y, Gu G, et al. Comparing 5G mobile stroke unit and emergency medical service in patients acute ischemic stroke eligible for t‐PA treatment: A prospective, single‐center clinical trial in Ya’an, China. Brain Behav 2023; 13(11): e3231.
[http://dx.doi.org/10.1002/brb3.3231] [PMID: 37632149]
[103]
Watts GF, Schwabe C, Scott R, et al. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: Phase 1 basket trial cohorts. Nat Med 2023; 29(9): 2216-23.
[http://dx.doi.org/10.1038/s41591-023-02494-2] [PMID: 37626170]
[104]
Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA 2022; 327(17): 1679.
[105]
Li Z, Wang Y, Liu Z, Luo N. Electronic visualized double-lumen endobronchial tube for situs inversus totalis: A case report and literature review. Medicine 2023; 102(48): e36295.
[http://dx.doi.org/10.1097/MD.0000000000036295] [PMID: 38050294]
[106]
Li D, Jiang Y, Zhuge C, Wu A. Treatment of aneurysmal artery with PED. A case report Medicine 2023; 102(48): e36377.
[http://dx.doi.org/10.1097/MD.0000000000036377] [PMID: 38050221]
[107]
Lugo Zamora IL, Lloyd C, Lorenzo-Castro S, Mussenden C, Hale G. Utilizing pharmacist-led telehealth services in ambulatory patients with heart failure. Innov Pharm 2023; 14(1): 12.
[http://dx.doi.org/10.24926/iip.v14i1.5306] [PMID: 38035317]
[108]
Olson A, Benfor B, Peden E. Stem cell therapy: A possible role in the treatment of patients with chronic limb-threatening ischemia? Methodist DeBakey Cardiovasc J 2023; 19(5): 69-72.
[http://dx.doi.org/10.14797/mdcvj.1291] [PMID: 38028971]
[109]
Volarevic V, Markovic BS, Gazdic M, et al. Ethical and safety issues of stem cell-based therapy. Int J Med Sci 2018; 15(1): 36-45.
[http://dx.doi.org/10.7150/ijms.21666] [PMID: 29333086]
[110]
King ML. Affordability, accountability, and accessibility in health care reform: Implications for cardiovascular and pulmonary rehabilitation. J Cardiopulm Rehabil Prev 2013; 33(3): 144-52.
[http://dx.doi.org/10.1097/HCR.0b013e31828f5602] [PMID: 23635835]
[111]
Husain MJ, Datta BK, Kostova D, et al. Access to cardiovascular disease and hypertension medicines in developing countries: An analysis of essential medicine lists, price, availability, and affordability. J Am Heart Assoc 2020; 9(9): e015302.
[http://dx.doi.org/10.1161/JAHA.119.015302] [PMID: 32338557]
[112]
Javaid A, Zghyer F, Kim C, et al. Medicine 2032: The future of cardiovascular disease prevention with machine learning and digital health technology. Am J Prev Cardio 2022; 12: 100379.
[http://dx.doi.org/10.1016/j.ajpc.2022.100379] [PMID: 36090536]
[113]
Rehman S, Rehman E, Ikram M, Jianglin Z. Cardiovascular disease (CVD): Assessment, prediction and policy implications. BMC Public Health 2021; 21(1): 1299.
[http://dx.doi.org/10.1186/s12889-021-11334-2] [PMID: 33388037]
[114]
Romiti S, Vinciguerra M, Saade W, Cortajarena AI, Greco E. Artificial Intelligence (AI) and cardiovascular diseases: An unexpected alliance. Cardiol Res Pract 2020; 2020: 1-8.
[http://dx.doi.org/10.1155/2020/4972346] [PMID: 32676206]
[115]
Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med 2020; 382(25): e102.
[http://dx.doi.org/10.1056/NEJMoa2007621] [PMID: 32356626]
[116]
Johnson KB, Wei WQ, Weeraratne D, et al. Precision medicine, AI, and the future of personalized health care. Clin Transl Sci 2021; 14(1): 86-93.
[http://dx.doi.org/10.1111/cts.12884] [PMID: 32961010]
[117]
Brewer LC, Fortuna KL, Jones C, et al. Back to the future: Achieving health equity through health informatics and digital health. JMIR Mhealth Uhealth 2020; 8(1): e14512.
[http://dx.doi.org/10.2196/14512] [PMID: 31934874]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy